Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large ...

Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...

ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support ...

Vicks accrued a total of 4.3 billion impressions on an estimated national TV ad spend of $18.9 million. The top network for ...

Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already ...

Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad ...

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares ...

McDonald’s Netherlands served up an AI-generated ad this holiday season, and the internet was quick to make the fast-food giant regret that decision. The commercial in question shows various ...

Bank of America's low payout ratio means this is a dividend you can count on. AbbVie's raking in money with immunology drugs Skyrizi and Rinvoq. Enterprise Products Partners maintains 50,000 miles of ...

AbbVie raised its dividend for 13 straight years with a 13% CAGR over the past decade. The current yield stands at 2.9%. Skyrizi and Rinvoq are projected to reach $31B in combined sales by 2027. The ...

This is read by an automated voice. Please report any issues or inconsistencies here. People aren’t lovin’ it. McDonald’s was forced to pull down an AI-generated Christmas commercial from YouTube ...